File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment of duodenal ulcer with antacid and sulpiride. A double-blind controlled study

TitleTreatment of duodenal ulcer with antacid and sulpiride. A double-blind controlled study
Authors
Issue Date1979
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro
Citation
Gastroenterology, 1979, v. 76 n. 2, p. 315-322 How to Cite?
AbstractThe effect of aluminum-magnesium hydroxide tablets (800 mg seven times per day) and that of sulpiride, a hypothalamic neuroleptic, were studied in 101 patients with duodenal ulcer in a double-blind controlled 4-wk trial. Significantly more of the patients treated with antacid, sulpiride or antacid-sulpiride combination showed a greater than 50% reduction in ulcer size than did the patients treated with placebo. However, only in the antacid- and antacid-sulpiride-treated groups did the ulcer, with and without residual inflammation, disappear statistically more often than in the placebo-treated group. Furthermore, only in the antacid-sulpiride-treated group did complete healing, with no trace of inflammation, occur statistically more often than in the placebo-treated group. Disappearance of ulcer pain was likewise statistically more frequent in the antacid-sulpiride group than in the placebo-treated group. Antacid therapy with aluminum-magnesium hydroxide tablets appears to accelerate the rate of ulcer healing. Sulpiride appears to have a minor but definite synergism with antacids. Cigarette smoking affected ulcer healing adversely; on the other hand, factors favorable to healing were the early onset age of ulcer symptoms and acid hypersecretion. Male patients also healed more favorably than females.
Persistent Identifierhttp://hdl.handle.net/10722/161641
ISSN
2015 Impact Factor: 18.187
2015 SCImago Journal Rankings: 7.170
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLam, SKen_US
dc.contributor.authorLam, KCen_US
dc.contributor.authorLai, CLen_US
dc.date.accessioned2012-09-05T05:13:26Z-
dc.date.available2012-09-05T05:13:26Z-
dc.date.issued1979en_US
dc.identifier.citationGastroenterology, 1979, v. 76 n. 2, p. 315-322en_US
dc.identifier.issn0016-5085en_US
dc.identifier.urihttp://hdl.handle.net/10722/161641-
dc.description.abstractThe effect of aluminum-magnesium hydroxide tablets (800 mg seven times per day) and that of sulpiride, a hypothalamic neuroleptic, were studied in 101 patients with duodenal ulcer in a double-blind controlled 4-wk trial. Significantly more of the patients treated with antacid, sulpiride or antacid-sulpiride combination showed a greater than 50% reduction in ulcer size than did the patients treated with placebo. However, only in the antacid- and antacid-sulpiride-treated groups did the ulcer, with and without residual inflammation, disappear statistically more often than in the placebo-treated group. Furthermore, only in the antacid-sulpiride-treated group did complete healing, with no trace of inflammation, occur statistically more often than in the placebo-treated group. Disappearance of ulcer pain was likewise statistically more frequent in the antacid-sulpiride group than in the placebo-treated group. Antacid therapy with aluminum-magnesium hydroxide tablets appears to accelerate the rate of ulcer healing. Sulpiride appears to have a minor but definite synergism with antacids. Cigarette smoking affected ulcer healing adversely; on the other hand, factors favorable to healing were the early onset age of ulcer symptoms and acid hypersecretion. Male patients also healed more favorably than females.en_US
dc.languageengen_US
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastroen_US
dc.relation.ispartofGastroenterologyen_US
dc.subject.meshAdministration, Oralen_US
dc.subject.meshAdulten_US
dc.subject.meshAluminum Hydroxide - Administration & Dosage - Adverse Effects - Therapeutic Useen_US
dc.subject.meshAntacids - Therapeutic Useen_US
dc.subject.meshCapsulesen_US
dc.subject.meshClinical Trials As Topicen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDrug Evaluationen_US
dc.subject.meshDuodenal Ulcer - Drug Therapyen_US
dc.subject.meshEndoscopyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMagnesium Hydroxide - Administration & Dosage - Adverse Effects - Therapeutic Useen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPatient Complianceen_US
dc.subject.meshPatient Dropoutsen_US
dc.subject.meshPlacebosen_US
dc.subject.meshSulpiride - Administration & Dosage - Adverse Effects - Therapeutic Useen_US
dc.subject.meshTabletsen_US
dc.subject.meshWound Healing - Drug Effectsen_US
dc.titleTreatment of duodenal ulcer with antacid and sulpiride. A double-blind controlled studyen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid365665-
dc.identifier.scopuseid_2-s2.0-0018388016en_US
dc.identifier.volume76en_US
dc.identifier.issue2en_US
dc.identifier.spage315en_US
dc.identifier.epage322en_US
dc.identifier.isiWOS:A1979GE75900013-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLam, SK=7402279473en_US
dc.identifier.scopusauthoridLam, KC=55106365400en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats